Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis

Sphere-shaped ZnO photocatalyst synthesis for enhanced degradation of the Quinolone antibiotic, Ofloxacin, under UV irradiation

The sphere-shaped zinc oxide (ZnO) photocatalyst was synthesized by the homogeneous precipitation method, using Zn(CH3COO)2·2H2O as a zinc precursor and NH4OH as a precipitating agent. The morphology and crystal structure of the prepared ZnO sample were studied by XRD, SEM, FT-IR, XPS, zeta potential measurements, and a low-temperature nitrogen adsorption-desorption technique. The optical characteristics of ZnO were determined by UV - Vis diffuse reflectance spectroscopy. ZnO photocatalyst performance of up to 100% within 210 min was observed in the photodegradation of the ofloxacin antibiotic under ultraviolet (UV) irradiation. The effect of antibiotic concentration, heavy metal ions, and water sources on the photocatalytic activity of ZnO demonstrated both the potential of its application under different conditions, and a good adaptability of this photocatalyst. The photodegradation reaction correlated well with the first-order kinetics model, with a rate constant of 0.0173 min-1. The reusability of the photocatalyst was verified after three cycles of use. Admittedly, photogenerated electrons and holes played a key role in removal of the antibiotic. This work showed the suitability of prepared ZnO for antibiotic removal, and its potential use for environmental protection.

Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans

In the recent decade, scientific communities have toiled to tackle the emerging burden of drug-resistant tuberculosis (DR-TB) and rapidly growing opportunistic nontuberculous mycobacteria (NTM). Among these, two neglected mycobacteria species of the Acinetobacter family, Mycobacterium leprae and Mycobacterium ulcerans, are the etiological agents of leprosy and Buruli ulcer infections, respectively, and fall under the broad umbrella of neglected tropical diseases (NTDs). Unfortunately, lackluster drug discovery efforts have been made against these pathogenic bacteria in the recent decade, resulting in the discovery of only a few countable hits and majorly repurposing anti-TB drug candidates such as telacebec (Q203), P218, and TB47 for current therapeutic interventions. Major ignorance in drug candidate identification might aggravate the dramatic consequences of rapidly spreading mycobacterial NTDs in the coming days. Therefore, this Review focuses on an up-to-date account of drug discovery efforts targeting selected druggable targets from both bacilli, including the accompanying challenges that have been identified and are responsible for the slow drug discovery. Furthermore, a succinct discussion of the all-new possibilities that could be alternative solutions to mitigate the neglected mycobacterial NTD burden and subsequently accelerate the drug discovery effort is also included. We anticipate that the state-of-the-art strategies discussed here may attract major attention from the scientific community to navigate and expand the roadmap for the discovery of next-generation therapeutics against these NTDs.